This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 6.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 5.61% and 3.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.
OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed the most recent trading day at $3.51, moving +0.86% from the previous trading session.
OPKO Health (OPK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -1.25% move from the prior day.
OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -266.67% and 19.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.
Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab
by Zacks Equity Research
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
Analysts Estimate OPKO Health (OPK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $3.04 in the latest trading session, marking a -0.65% move from the prior day.
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis
by Zacks Equity Research
Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.
OPKO Health (OPK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $2.87 in the latest trading session, marking a -1.37% move from the prior day.
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
by Zacks Equity Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment
by Zacks Equity Research
Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients
by Zacks Equity Research
Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.
OPKO Health (OPK) Receives FDA Nod for the 4Kscore Test
by Zacks Equity Research
OPKO Health (OPK) gets FDA nod for its 4Kscore Test that will further validate its value of being an important tool in the diagnosis of prostate cancer.
OPKO Health's (OPK) Arm Declares Readiness for COVID-19 Testing
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories announces preparedness with respect to COVID-19 testing in the advent of the Omicron Variant.
OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.